Loading…
Employees: 789
Size PKU Healthcare (000788.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $489M, the 3911th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥5.47 on 6 Nov 2026.
Performance Over six months the shares fell 10.6%, against -22.0% for the median peer and -16.4% for the China market (cap-weighted) — 8th highest of 20 in its peer set.
Growth Revenue fell 48.6% over the last twelve months (peer median +4.5%); the operating margin is 4.6% (peer median 0.5%).
Valuation It trades at 2.5× enterprise value to sales against a peer median of 3.7× (7th cheapest of 20).
Price implies For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is -6%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 6.0 points above its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥904M | CN¥1.47B | CN¥2.05B | CN¥2.18B | CN¥2.07B |
| Revenue growth | — | -28% | -6% | +6% | — |
| Gross profit | CN¥335M | CN¥396M | CN¥531M | CN¥670M | CN¥736M |
| EBITDA | n/a | CN¥172M | CN¥263M | CN¥148M | CN¥142M |
| Net income | CN¥20.7M | CN¥82.9M | CN¥138M | CN¥44.4M | CN¥55.6M |
| Free cash flow | CN¥551M | CN¥339M | CN¥308M | CN¥58.6M | CN¥244M |
| Capital expenditure | CN¥27.4M | CN¥48.8M | CN¥39.4M | CN¥63.2M | CN¥35.3M |
| Total debt | CN¥138M | CN¥72.7M | CN¥106M | CN¥145M | CN¥256M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000788.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.2% | -11.3% | 4th highest of 21 |
| 6-month return | -10.6% | -22.0% | 8th highest of 20 |
| Distance from 52-week high | -31.5% | -46.0% | 4th highest of 21 |
| Revenue growth (TTM) | -48.6% | +4.5% | 2nd lowest of 20 |
| Operating margin | 4.6% | 0.5% | 8th highest of 20 |
| EV / Sales | 2.5× | 3.7× | 7th cheapest of 20 |
| Growth the price implies (Req g, 7 yrs) | -2.6% | 3.7% | 4th least demanding of 9 |
| Growth delivered (Del g) | -5.6% | +1.2% | 2nd lowest of 9 |
| Hurdle (Req g minus delivered) | +3.0 pp | -1.6 pp | 4th most demanding of 9 |
| ROIC minus cost of capital | +6.0 pp | -4.8 pp | 3rd highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| PKU Healthcare 000788.SZ | China | $489M | -11% | -49% | 5% | 2.5× | -2.6% | -5.6% |
| Electra Therapeutics ETRA | United States | $490M | n/a | n/a | n/a | n/a | n/a | n/a |
| Daewoong 003090.KS | South Korea | $485M | -29% | +5% | 11% | 0.9× | n/a | n/a |
| Tong Ren Tang Technologies 1666.HK | Hong Kong | $484M | -23% | -14% | 12% | 0.5× | -18.6% | +6.3% |
| Shanghai MicuRx Pharmaceutical 688373.SS | China | $495M | -16% | +23% | -61% | 19.6× | n/a | n/a |
| SMS Pharmaceuticals SMSPHARMA.NS | India | $495M | +18% | +10% | 15% | 5.2× | n/a | n/a |
| Shanghai Shenqi Pharmaceutical Investment Management 600613.SS | China | $483M | +9% | -4% | 3% | 1.4× | 13.4% | +1.4% |
| Cheng Du Sheng Nuo Biotec 688117.SS | China | $496M | -44% | +51% | 27% | 3.9× | 1.7% | +14.5% |
| Alpha Teknova TKNO | United States | $482M | +104% | +12% | -35% | 11.3× | n/a | n/a |
| CytomX Therapeutics CTMX | United States | $477M | -45% | -87% | -477% | 8.3× | n/a | n/a |
| Elixiron Immunotherapeutics (Cayman) 7871.TWO | Taiwan | $477M | +62% | +10,947% | -194% | 132.2× | n/a | n/a |
| Xiangxue Pharmaceutical 300147.SZ | China | $502M | -49% | +3% | -39% | 3.3× | 47.1% | -12.3% |
| Hainan Shuangcheng Pharmaceuticals 002693.SZ | China | $476M | -10% | +40% | 13% | 11.1× | 44.5% | +1.0% |
| Jiangsu Sihuan Bioengineering 000518.SZ | China | $476M | +7% | -17% | -28% | 11.5× | n/a | n/a |
| REGENXBIO RGNX | United States | $503M | -28% | +12% | -94% | 3.7× | n/a | n/a |
| Pulike Biological Engineering 603566.SS | China | $475M | -22% | -9% | 5% | 2.5× | 5.7% | +3.3% |
| YungShin Global 3705.TW | Taiwan | $474M | +7% | -8% | 15% | 1.9× | -4.9% | +0.7% |
| Gyre Therapeutics GYRE | United States | $505M | -36% | +17% | -11% | 4.1× | n/a | n/a |
| Cachet Pharmaceutical 002462.SZ | China | $471M | -22% | -14% | 0% | 0.2× | -8.9% | -3.4% |
| Kexing Biopharm 688136.SS | China | $470M | -38% | -14% | -12% | 3.1× | n/a | n/a |
| Zhejiang Huakang Pharmaceutical 605077.SS | China | $470M | -39% | +35% | 4% | 1.2× | n/a | n/a |